Skip to main content Accessibility help
×
Home
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 1
  • Print publication year: 2014
  • Online publication date: June 2014

Chapter 26 - Treatment approaches for lacunar strokes

from Section 4 - Therapeutic aspects: prevention, future directions, and possibilities

References

1. Petty GW, Brown RD, Jr., Whisnant JP, et al. Ischemic stroke subtypes: a population-based study of functional outcome, survival, and recurrence. Stroke 2000;31:1062–1068.
2. O’Brien JT, Erkinjuntti T, Reisberg B, et al. Vascular cognitive impairment. Lancet Neurol 2003;2:89–98.
3. Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol 2009;8:1006–1018.
4. Mok VC, Lau AY, Wong A, et al. Long-term prognosis of Chinese patients with a lacunar infarct associated with small vessel disease: a five-year longitudinal study. Int J Stroke 2009;4:81–88.
5. Sacco RL, Kargman DE, Zamanillo MC. Race–ethnic differences in stroke risk factors among hospitalized patients with cerebral infarction: the Northern Manhattan Stroke Study. Neurology 1995;45:659–663.
6. Samanci N, Dora B, Kizilay F, et al. Factors affecting one year mortality and functional outcome after first ever ischemic stroke in the region of Antalya, Turkey (a hospital-based study). Acta Neurol Belg 2004;104:154–160.
7. Soda T, Nakayasu H, Maeda M, et al. Stroke recurrence within the first year following cerebral infarction – Tottori University Lacunar Infarction Prognosis Study (TULIPS). Acta Neurol Scand 2004;110:343–349.
8. Worley KL, Lalonde DR, Kerr DR, Benavente O, Hart RG. Survey of the causes of stroke among Mexican Americans in South Texas. Tex Med 1998;94:62–67.
9. Yokota C, Minematsu K, Hasegawa Y, Yamaguchi T. Long-term prognosis, by stroke subtypes, after a first-ever stroke: a hospital-based study over a 20-year period. Cerebrovasc Dis 2004;18:111–116.
10. Fisher CM. Lacunar strokes and infarcts: a review. Neurology 1982;32:871–876.
11. Lammie GA. Hypertensive cerebral small vessel disease and stroke. Brain Pathol 2002;12:358–370.
12. Feekes JA, Hsu SW, Chaloupka JC, Cassell MD. Tertiary microvascular territories define lacunar infarcts in the basal ganglia. Ann Neurol 2005;58:18–30.
13. Fisher CM. Lacunes: small, deep cerebral infarcts. Neurology 1965;15:774–784.
14. Fisher CM. The arterial lesions underlying lacunes. Acta Neuropathol 1968;12:1–15.
15. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010;9:689–701.
16. Benavente OR, White CL, Pearce L, et al. The Secondary Prevention of Small Subcortical Strokes (SPS3) study. Int J Stroke 2011;6:164–175.
17. Clavier I, Hommel M, Besson G, Noelle B, Perret JE. Long-term prognosis of symptomatic lacunar infarcts. A hospital-based study. Stroke 1994;25:2005–2009.
18. Nadeau SE, Jordan JE, Mishra SK, Haerer AF. Stroke rates in patients with lacunar and large vessel cerebral infarctions. J Neurol Sci 1993;114:128–137.
19. Gandolfo C, Moretti C, Dall’Agata D, et al. Long-term prognosis of patients with lacunar syndromes. Acta Neurol Scand 1986;74:224–229.
20. Hier DB, Foulkes MA, Swiontoniowski M, et al. Stroke recurrence within two years after ischemic infarction. Stroke 1991;22:155–161.
21. Miyao S, Takano A, Teramoto J, Takahashi A. Leukoaraiosis in relation to prognosis for patients with lacunar infarction. Stroke 1992;23:1434–1438.
22. Landi G, Cella E, Boccardi E, Musicco M. Lacunar versus non-lacunar infarcts: pathogenetic and prognostic differences. J Neurol Neurosurg Psych 1992;55:441–445.
23. Brainin M, Seiser A, Czvitkovits B, Pauly E. Stroke subtype is an age-independent predictor of first-year survival. Neuroepidemiology 1992;11:190–195.
24. Boiten J, Lodder J. Prognosis for survival, handicap and recurrence of stroke in lacunar and superficial infarction. Cerebrovasc Dis 1993;3:221–226.
25. Samuelsson M, Lindell D, Norrving B. Presumed pathogenetic mechanisms of recurrent stroke after lacunar infarction. Cerebrovasc Dis 1996;6:128–136.
26. Salgado AV, Ferro JM, Gouveia-Oliveira A. Long-term prognosis of first-ever lacunar strokes. A hospital-based study. Stroke 1996;27:661–666.
27. Yamamoto Y, Akiguchi I, Oiwa K, Hayashi M, Kimura J. Adverse effect of nighttime blood pressure on the outcome of lacunar infarct patients. Stroke 1998;29:570–576.
28. Staaf G, Lindgren A, Norrving B. Pure motor stroke from presumed lacunar infarct: long-term prognosis for survival and risk of recurrent stroke. Stroke 2001;32:2592–2596.
29. Eriksson SE, Olsson JE. Survival and recurrent strokes in patients with different subtypes of stroke: a 14-year follow-up study. Cerebrovasc Dis 2001;12:171–180.
30. Kazui S, Levi CR, Jones EF, et al. Lacunar stroke: transoesophageal echocardiographic factors influencing long-term prognosis. Cerebrovasc Dis 2001;12:325–330.
31. Yamamoto Y, Akiguchi I, Oiwa K, et al. Twenty-four-hour blood pressure and MRI as predictive factors for different outcomes in patients with lacunar infarct. Stroke 2002;33:297–305.
32. De Jong G, van Raak L, Kessels F, Lodder J. Stroke subtype and mortality. A follow-up study in 998 patients with a first cerebral infarct. J Clin Epidemiol 2003;56:262–268.
33. Jackson CA, Hutchison A, Dennis MS, et al. Differences between ischemic stroke subtypes in vascular outcomes support a distinct lacunar ischemic stroke arteriopathy: a prospective, hospital-based study. Stroke 2009;40:3679–3684.
34. Suto Y, Kowa H, Nakayasu H, et al. Relationship between three-year survival and functional outcome at discharge from acute-care hospitals in each subtype of first-ever ischemic stroke patients. Intern Med 2011;50:1377–1383.
35. Stead LG, Gilmore RM, Bellolio MF, et al. Cardioembolic but not other stroke subtypes predict mortality independent of stroke severity at presentation. Stroke Res Treat 2011;2011:281496.
36. Kwan MW, Mak W, Cheung RT, Ho SL. Ischemic stroke related to intracranial branch atheromatous disease and comparison with large and small artery diseases. J Neurological Sci 2011;303:80–84.
37. Ntaios G, Michel P. Temporal distribution and magnitude of the vulnerability period around stroke depend on stroke subtype. Cerebrovasc Dis 2011;32:246–253.
38. Melkas S, Putaala J, Oksala NK, et al. Small-vessel disease relates to poor poststroke survival in a 12-year follow-up. Neurology 2011;76:734–739.
39. Bamford J, Sandercock P, Jones L, Warlow C. The natural history of lacunar infarction: the Oxfordshire Community Stroke Project. Stroke 1987;18:545–551.
40. Sacco SE, Whisnant JP, Broderick JP, Phillips SJ, O’Fallon WM. Epidemiological characteristics of lacunar infarcts in a population. Stroke 1991;22:1236–1241.
41. Sacco RL, Shi T, Zamanillo MC, Kargman DE. Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: the Northern Manhattan Stroke Study. Neurology 1994;44:626–634.
42. Anderson CS, Jamrozik KD, Broadhurst RJ, Stewart-Wynne EG. Predicting survival for one year among different subtypes of stroke. Results from the Perth Community Stroke Study. Stroke 1994;25:1935–1944.
43. Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU. Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. Stroke 2001;32:2735–2740.
44. Hata J, Tanizaki Y, Kiyohara Y, et al. Ten year recurrence after first ever stroke in a Japanese community: the Hisayama study. J Neurol Neurosurg Psych 2005;76:368–372.
45. Bejot Y, Catteau A, Caillier M, et al. Trends in incidence, risk factors, and survival in symptomatic lacunar stroke in Dijon, France, from 1989 to 2006: a population-based study. Stroke 2008;39:1945–1951.
46. Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. New Engl J Med 2001;345:1444–1451.
47. Sacco RL, Prabhakaran S, Thompson JL, et al. Comparison of warfarin versus aspirin for the prevention of recurrent stroke or death: subgroup analyses from the Warfarin–Aspirin Recurrent Stroke study. Cerebrovasc Dis 2006;22:4–12.
48. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331–337.
49. Amarenco P, Bogousslavsky J, Callahan A, 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. New Engl J Med 2006;355:549–559.
50. Sacco RL, Diener HC, Yusuf S, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. New Engl J Med 2008;359:1238–1251.
51. Shinohara Y, Katayama Y, Uchiyama S, et al. Cilostazol for Prevention of Secondary Stroke (CSPS2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010;9:959–968.
52. Benavente OR, Hart RG, McClure LA, et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. New Engl J Med 2012;367:817–825.
53. Norrving B. Long-term prognosis after lacunar infarction. Lancet Neurol 2003;2:238–245.
54. Jackson C, Sudlow C. Comparing risks of death and recurrent vascular events between lacunar and non-lacunar infarction. Brain 2005;128(Pt 11):2507–2517.
55. Norrving B. Lacunar infarcts: no black holes in the brain are benign. Pract Neurol 2008;8:222–228.
56. Jacova C, Pearce LA, Costello R, et al. Cognitive impairment in lacunar strokes: the SPS3 trial. Ann Neurol 2012;72:351–362.
57. Jauch EC, Saver JL, Adams HP, Jr., et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013;44:870–947.
58. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. New Engl J Med 1995;333:1581–1587.
59. Hsia AW, Sachdev HS, Tomlinson J, Hamilton SA, Tong DC. Efficacy of IV tissue plasminogen activator in acute stroke: does stroke subtype really matter? Neurology 2003;61:71–75.
60. Cocho D, Belvis R, Marti-Fabregas J, et al. Does thrombolysis benefit patients with lacunar syndrome? Eur Neurol 2006;55:70–73.
61. Fluri F, Hatz F, Rutgers MP, et al. Intravenous thrombolysis in patients with stroke attributable to small artery occlusion. Eur J Neurol 2010;17:1054–1060.
62. Mustanoja S, Meretoja A, Putaala J, et al. Outcome by stroke etiology in patients receiving thrombolytic treatment: descriptive subtype analysis. Stroke 2011;42:102–106.
63. Ohara T, Nagakane Y, Tanaka E, et al. Clinical and radiological features of stroke patients with poor outcomes who do not receive intravenous thrombolysis because of mild symptoms. Eur Neurol 2012;69:4–7.
64. Smith EE, Fonarow GC, Reeves MJ, et al. Outcomes in mild or rapidly improving stroke not treated with intravenous recombinant tissue-type plasminogen activator: findings from Get With The Guidelines–Stroke. Stroke 2011;42:3110–3115.
65. Neumann-Haefelin T, Hoelig S, Berkefeld J, et al. Leukoaraiosis is a risk factor for symptomatic intracerebral hemorrhage after thrombolysis for acute stroke. Stroke 2006;37:2463–2466.
66. Palumbo V, Boulanger JM, Hill MD, Inzitari D, Buchan AM. Leukoaraiosis and intracerebral hemorrhage after thrombolysis in acute stroke. Neurology 2007;68:1020–1024.
67. Demchuk AM, Khan F, Hill MD, et al. Importance of leukoaraiosis on CT for tissue plasminogen activator decision making: evaluation of the NINDS rt-PA stroke study. Cerebrovasc Dis 2008;26:120–125.
68. Shoamanesh A, Kwok CS, Lim PA, Benavente OR. Postthrombolysis intracranial hemorrhage risk of cerebral microbleeds in acute stroke patients: a systematic review and meta-analysis. Int J Stroke 2013;8:348–356.
69. Chalela JA, Kang DW, Warach S. Multiple cerebral microbleeds: MRI marker of a diffuse hemorrhage-prone state. J Neuroimaging 2004;14:54–57.
70. Del Bene A, Palumbo V, Lamassa M, et al. Progressive lacunar stroke: review of mechanisms, prognostic features, and putative treatments. Int J Stroke 2012;7:321–329.
71. Donnan GA, Bladin PF, Berkovic SF, Longley WA, Saling MM. The stroke syndrome of striatocapsular infarction. Brain 1991;114(Pt 1A):51–70.
72. Donnan GA, O’Malley HM, Quang L, Hurley S, Bladin PF. The capsular warning syndrome: pathogenesis and clinical features. Neurology 1993;43:957–962.
73. Paul NL, Simoni M, Chandratheva A, Rothwell PM. Population-based study of capsular warning syndrome and prognosis after early recurrent TIA. Neurology 2012;79:1356–1362.
74. Kennedy J, Hill MD, Ryckborst KJ, et al. Fast Assessment of Stroke and Transient ischaemic attack to prevent Early Recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol 2007;6:961–969.
75. Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. New Engl J Med 2013;369:11–19.
76. Khan A, Kasner SE, Lynn MJ, Chimowitz MI. Risk factors and outcome of patients with symptomatic intracranial stenosis presenting with lacunar stroke. Stroke 2012;43:1230–1233.
77. Bailey EL, Smith C, Sudlow CL, Wardlaw JM. Pathology of lacunar ischemic stroke in humans – a systematic review. Brain Pathol 2012;22:583–591.
78. Bousser MG, Eschwege E, Haguenau M, et al. “AICLA” controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke 1983;14:5–14.
79. Gent M, Blakely JA, Easton JD, et al. The Canadian–American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989;1:1215–1220.
80. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke. Lancet 1997;349:1641–1649.
81. Gotoh F, Tohgi H, Hirai S, et al. Cilostazol Stroke Prevention Study: a placebo-controlled doubleblind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 2000;9:147–157.
82. Gorelick PB, Richardson D, Kelly M, et al. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. JAMA 2003;289:2947–2957.
83. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006;367:1665–1673.
84. Bousser MG, Amarenco P, Chamorro A, et al. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet 2011;377:2013–2022.
85. Shinohara Y, Gotoh F, Tohgi H, et al. Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients. Subgroup analysis of the Cilostazol Stroke Prevention Study. Cerebrovasc Dis 2008;26:63–70.
86. Harker LA, Marzec UM, Kelly AB, et al. Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates. Circulation 1998;98:2461–2469.
87. Makkar RR, Eigler NL, Kaul S, et al. Effects of clopidogrel, aspirin and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis. Eur Heart J 1998;19:1538–1546.
88. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New Engl J Med 2001;345:494–502.
89. Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42:227–276.
90. Ebrahim S, Sung J, Song YM, et al. Serum cholesterol, haemorrhagic stroke, ischaemic stroke, and myocardial infarction: Korean National Health System Prospective Cohort Study. BMJ 2006;333:22.
91. Iso H, Jacobs DR, Jr., Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350 977 men screened for the multiple risk factor intervention trial. New Engl J Med 1989;320:904–910.
92. Collins R, Armitage J, Parish S, et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004;363:757–767.
93. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 2009;8:453–463.
94. Amarenco P, Benavente O, Goldstein LB, et al. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes. Stroke 2009;40:1405–1409.
95. Goldstein LB, Amarenco P, Szarek M, et al. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology 2008;70(24 Pt 2):2364–2370.
96. O’Donnell MJ, Xavier D, Liu L, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet 2010;376:112–123.
97. Collins R, Peto R, Godwin J, MacMahon S. Blood pressure and coronary heart disease. Lancet 1990;336:370–371.
98. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827–838.
99. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765–774.
100. PROGRESS Management Committee. PROGRESS – The Perindopril Protection aGainst Recurrent Stroke Study: characteristics of the study population at baseline. J Hypertens 1999;17:1647–1655.
101. Gueyffier F, Boissel JP, Boutitie F, et al. Effect of antihypertensive treatment in patients having already suffered from stroke. Gathering the evidence. The INDANA (INdividual Data ANalysis of Antihypertensive intervention trials) Project Collaborators. Stroke 1997;28:2557–2562.
102. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke 2003;34:2741–2748.
103. Benavente OR, Coffey CS, Conwit R, et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet 2013;382:507–515.
104. Jackson CA, Hutchison A, Dennis MS, et al. Differing risk factor profiles of ischemic stroke subtypes: evidence for a distinct lacunar arteriopathy? Stroke 2010;41:624–629.
105. Micheli S, Agnelli G, Palmerini F, et al. Need for extensive diagnostic work-up for patients with lacunar stroke. J Neurol 2008;255:637–642.
106. Apostolakis S, Lane DA, Buller H, Lip GY. Comparison of the CHADS2, CHADS2–VASc and HAS–BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial. Thromb Haemostasis 2013;110:1074–1079.
107. Rajapakse A, Rajapakse S, Sharma JC. Is investigating for carotid artery disease warranted in non-cortical lacunar infarction? Stroke 2011;42:217–220.
108. Mead GE, Lewis SC, Wardlaw JM, Dennis MS, Warlow CP. Severe ipsilateral carotid stenosis and middle cerebral artery disease in lacunar ischaemic stroke: innocent bystanders? J Neurol 2002;249:266–271.
109. Inzitari D, Eliasziw M, Sharpe BL, Fox AJ, Barnett HJ. Risk factors and outcome of patients with carotid artery stenosis presenting with lacunar stroke. North American Symptomatic Carotid Endarterectomy Trial Group. Neurology 2000;54:660–666.
110. Barnett HJ, Meldrum HE, Eliasziw M. The appropriate use of carotid endarterectomy. CMAJ 2002;166:1169–1179.